Acute Profound Thrombocytopenia after Using Abciximab for No-Reflow during Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction
Korean Circulation Journal
; : 557-560, 2013.
Article
en En
| WPRIM
| ID: wpr-24540
Biblioteca responsable:
WPRO
ABSTRACT
Glycoprotein IIb/IIIa antagonists are well established for their effectiveness in improving clinical outcomes in acute coronary syndrome patients undergoing percutaneous coronary intervention. Acute profound thrombocytopenia is a rare complication of abciximab. We present a case which was managed successfully for the rare complication of acute profound thrombocytopenia after using abciximab and an intra-aortic balloon pump for the treatment of a no-reflow phenomenon and consecutive cardiogenic shock during primary percutaneous coronary intervention.
Palabras clave
Texto completo:
1
Base de datos:
WPRIM
Asunto principal:
Choque Cardiogénico
/
Trombocitopenia
/
Fragmentos Fab de Inmunoglobulinas
/
Síndrome Coronario Agudo
/
Fenómeno de no Reflujo
/
Intervención Coronaria Percutánea
/
Anticuerpos Monoclonales
/
Infarto del Miocardio
Límite:
Humans
Idioma:
En
Revista:
Korean Circulation Journal
Año:
2013
Tipo del documento:
Article